Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025

Core Insights - Vivoryon Therapeutics N.V. presented meta-analysis data for its lead drug varoglutamstat at the 62nd ERA Congress, highlighting significant improvements in kidney function [1][2][3] Group 1: Drug Development and Efficacy - Varoglutamstat is a first-in-class glutaminyl cyclase (QPCT/L) inhibitor with notable anti-inflammatory and anti-fibrotic effects [3] - The Phase 2 studies, VIVIAD and VIVA-MIND, demonstrated statistically significant and clinically meaningful improvements in estimated glomerular filtration rate (eGFR) in elderly patients, with effects sustained from week 24 to week 96 [3] - The meta-analysis indicated a larger effect size in participants with diabetes compared to those without [3] Group 2: Future Plans - The next step involves a dedicated Phase 2b trial focusing on patients with diabetic kidney disease, aiming to assess efficacy on eGFR and gather data on proteinuria and other kidney-specific markers [4] Group 3: Presentation Details - The presentation took place on June 6, 2025, at 8:15 am CEST in Vienna, Austria, led by Frank Weber, CEO of Vivoryon Therapeutics [5]